The revolutionary impact of immune checkpoint inhibitors (ICIs) has transformed cancer care, yielding unprecedented durable responses across a spectru
Read Full Article To Earn PointsDaily news to keep you up to date
Participate and win exciting prizes
Participate and win cash vouchers
Get updates on the latest events happening around the world
1.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
2.
One possible target in acute myeloid leukemia is the reductive carboxylation of glutamine.
3.
Ultrasonography of hepatocellular carcinoma: From diagnosis to prognosis
4.
Discovery of a new biomarker for early detection of bladder cancer in both dogs and humans
5.
Second Malignancy Risk With CAR T-Cell Therapy on Par With Other Treatments
1.
Tumor Evolution: Signaling, Cancer Cell Plasticity, and Intratumor Heterogeneity
2.
Cardio-Oncology in Survivors: Safeguarding Hearts Through Multidisciplinary Care
3.
Oncology Drug Trends 2025: FDA Approvals, Immuno-Oncology, and Clinical Trial Insights
4.
The Silent Danger of Hematoma: How to Identify and Treat This Potentially Serious Condition
5.
Real-World Oncology Insights: CAR-T, Immunotherapy, PROs, and Digital Tools
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment
2.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation